AEON Biopharma Submits IND To FDA For Comparative Pharmacodynamic Study Of ABP-450
Benzinga Newsdesk 6 hours ago
BiotechGeneralNewsFDA
Submission advances ABP-450 biosimilar development program following recent FDA Type 2b meetingPlanned CMAP study designed to generate clinical evidence comparing the neuromuscular activity of ABP-450 and BOTOX®; study
Submission advances ABP-450 biosimilar development program following recent FDA Type 2b meeting
Planned CMAP study designed to generate clinical evidence comparing the neuromuscular activity of ABP-450 and BOTOX®; study initiation expected in Q1’2027